Saturday 17 October 2026
Export TLX’s income statement to Excel — free account
Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited’s revenue for fiscal 2025 (year ended December 2025) was $803.8 million, up 55.6% from fiscal 2024. Insiders bought in the last twelve months.
10.69
0.12
+1.14%
Follow TLX
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | 14.44 | 7.49 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | 19.99 | 30.36 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 441 | 554 | 1,184 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.76 | 0.93 | 0.68 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | 334 | 517 | 804 | ||||
| Gross margin, % | — | — | — | — | — | — | — | 62.56 | 65.08 | 53.05 | |||||
| EBT | — | — | — | — | — | — | — | 2 | 38 | (5) | |||||
| EBT margin, % | — | — | — | — | — | — | — | 0.61 | 7.34 | (0.66) | |||||
| Net income | — | — | — | — | — | — | — | 2 | 38 | (5) | |||||
| Depreciation | — | — | — | — | — | — | — | 4 | 5 | 21 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | 1.05 | 1.56 | 2.38 | ||||
| Earnings | — | — | — | — | — | — | — | 0.01 | 0.10 | (0.02) | |||||
| Cash flow | — | — | — | — | — | — | — | 0.05 | 0.08 | (0.05) | |||||
| Capex | — | — | — | — | — | — | — | (0.02) | (0.07) | (0.13) | |||||
| Free cash flow | — | — | — | — | — | — | — | 0.03 | 0.02 | (0.18) | |||||
| Book value | — | — | — | — | — | — | — | 0.31 | 1.07 | 1.23 | |||||
| Shares, m | — | — | — | — | — | — | — | 319 | 331 | 338 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | |||||
| EV/Sales | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | |||||
| EV/FCF | — | — | — | — | — | — | — | 0.00 | 0.00 | 32.89 | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | 16 | 27 | (17) | ||||
| Capex | — | — | — | — | — | — | — | (7) | (22) | (44) | |||||
| Free cash flow | — | — | — | — | — | — | — | 9 | 5 | (61) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | 45 | 365 | 99 | ||||
| Total debt | — | — | — | — | — | — | — | 11 | 359 | 462 | |||||
| Net debt | — | — | — | — | — | — | — | (71) | (81) | 320 | |||||
| Shareholders’ equity | — | — | — | — | — | — | — | 99 | 353 | 415 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | 0.00 | 5.57 | (0.68) | ||||
| ROIC | — | — | — | — | — | — | — | 23.28 | 12.70 | 2.53 | |||||
| ROE | — | — | — | — | — | — | — | 0.00 | 14.91 | (1.85) | |||||
Negative figures in brackets.
Fiscal years to Dec 2025
Charts ten years each
Telix Pharmaceuticals Limited vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| LEGN Legend Biotech Corporation Sponsored ADR | $3.8B | — (loss-making) | 112× | +51.90% (above 0%: growing) | n/m | −26.79% (below 0%: shrinking) | 64.54% | 14.37% | Compare |
| TNGX Tango Therapeutics, Inc. | $3.8B | — (loss-making) | — (loss-making) | −100.00% (below 0%: shrinking) | n/m | −4.58% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| RLAY Relay Therapeutics, Inc. | $3.8B | — (loss-making) | — (loss-making) | −95.44% (below 0%: shrinking) | n/m | +2.13% (above 0%: growing) | 100.00% | (25,949.71%) | Compare |
| ARQT Arcutis Biotherapeutics, Inc. | $3.7B | 131× | 196× | +59.33% (above 0%: growing) | n/m | +227.96% (above 0%: growing) | 91.58% | 12.65% | Compare |
| TLX Telix Pharmaceuticals Limited | $3.6B | — | — | — | — | −44.78% (below 0%: shrinking) | — | — | |
| TARS Tarsus Pharmaceuticals, Inc. | $3.5B | — (loss-making) | — (loss-making) | +69.41% (above 0%: growing) | n/m | +288.08% (above 0%: growing) | 93.03% | (11.45%) | Compare |
| VKTX Viking Therapeutics, Inc. | $3.5B | — (loss-making) | — | — | n/m | −165.98% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ACAD ACADIA Pharmaceuticals Inc. | $3.4B | 8.5× | 55.6× | +16.40% (above 0%: growing) | +12.50% (above 0%: growing) | +50.32% (above 0%: growing) | 90.81% | 12.29% | Compare |
| XENE Xenon Pharmaceuticals Inc. | $3.3B | — (loss-making) | — (loss-making) | +100.70% (above 0%: growing) | n/m | −48.57% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| Median of peers | $3.6B | — | 112× | +51.90% | — | −1.22% | 91.20% | 0.00% |
Telix Pharmaceuticals Limited (TLX) key facts
- Concern: Telix Pharmaceuticals Limited reported a net loss of $5.3 million, or a loss of $0.02 per share, for fiscal 2025.
- Strength: Telix Pharmaceuticals Limited’s revenue for fiscal 2025 (year ended December 2025) was $803.8 million, up 55.6% from fiscal 2024.
- Telix Pharmaceuticals Limited (TLX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, TLX traded at $10.69, a market capitalization of $3.6 billion.
- Return on equity was −1.85% and debt-to-equity 1.18.
- Its Piotroski F-score is 1 out of 9 and its Altman Z-score is 2.72 (grey zone) for fiscal 2025.